Literature DB >> 15050160

The colon displays an absorptive capacity of tacrolimus.

K Nishi1, T Ishii, M Wada, S Amae, N Sano, M Nio, Y Hayashi.   

Abstract

PURPOSE: In our previous study, blood levels of orally administered tacrolimus were significantly higher in short bowel piglets than in control animals. It has been reported that the blood levels of tacrolimus are influenced by the metabolic activity of intestinal CYP3A4. If tacrolimus may be absorbed in the colon, direct administration of drug into this organ might be useful to augment bioavailability since the expression of CYP3A4 is low at this site. In the present study we evaluated the absorptive capacity of tacrolimus in the colon.
MATERIALS AND METHODS: Piglets were divided into four groups: groups 1 and 2 were controls (n = 11 and 3, respectively); group 3 underwent resection of the entire small intestine (n = 8); and group 4 had a catheter placed in the cecum (n = 4). In groups 1 and 3, tacrolimus was administered orally; in group 2 it was given intravenously; and in group 4 it was injected into cecum through the catheter from postoperative days 3 to 7. On day 7, blood samples were obtained for drug measurements to calculate the area under the concentration time curve (AUC) values.
RESULTS: The trough level and AUC values of tacrolimus in group 4 as well as in group 3 were significantly higher than those in group 1. In Group 4 animals showed a 60-minute time to peak concentration.
CONCLUSIONS: Tacrolimus is absorbed by the colon. Since the blood levels were not influenced by the metabolic activity in the graft bowel, direct administration of tacrolimus into the colon might be useful in small intestinal transplantation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15050160     DOI: 10.1016/j.transproceed.2003.12.013

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  3 in total

1.  The effects of tacrolimus on colonic anastomotic healing in rats.

Authors:  D Raptis; I Mantzoros; M G Pramateftakis; K Despoudi; T Zaraboukas; G Koliakos; I Kanellos; Ch Lazarides
Journal:  Int J Colorectal Dis       Date:  2011-11-09       Impact factor: 2.571

2.  THE CHALLENGE OF ACHIEVING ADEQUATE ORAL IMMUNOSUPPRESSION IN A RENAL TRANSPLANT RECIPIENT WHO DEVELOPS SHORT BOWEL SYNDROME (SBS).

Authors:  O M McCloskey; A Woodman; A Mitchell; J Smyth
Journal:  Ulster Med J       Date:  2018-10-01

3.  Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgery in end-stage renal disease and transplant patients: a pilot study.

Authors:  Christin C Rogers; Rita R Alloway; J Wesley Alexander; Michael Cardi; Jennifer Trofe; Alexander A Vinks
Journal:  Clin Transplant       Date:  2008 May-Jun       Impact factor: 2.863

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.